Dose Finding Study of a Low Molecular Weight Heparin, Innohep, in Haemodialysis

Summary

A pilot investigation was performed with Innohep, a low molecular weight (LMWH) preparation (peak maximum molecular mass 3,000-6,000), to determine possible dose regimens for patients undergoing regular maintenance haemodialysis for chronic renal failure. Results from this study suggested that suppression of macroscopic clot formation and fibrinopeptide A (FPA), a marker of fibrin formation, could be achieved following bolus injections rather than bolus injections and an infusion. On the basis of these preliminary findings, a randomised crossover study was performed in eight patients undergoing regular maintenance haemodialysis for 5-7 h to determine the effective antithrombotic dose of this LMWH. Single i.v. bolus doses of 1,250 AFXa u, 2,500 AFXa u and 5,000 AFXa u (n = 7-8) were compared to an UFH regime of 5,000 iu + 1,500 iu/h. Excessive clot formation in the dialyser bubble trap, necessitating additional UFH to enable completion of a prolonged (up to 7 h) dialysis, was observed in all patients on the 1,250 AFXa u dose (mean duration of dialysis prior to UFH, 3 h) but in a single patient only receiving the other LMWH doses. A dose-related response in the AFXa activity, measured by chromogenic substrate (CS) assay was seen in the three LMWH groups, with levels declining significantly (p <0.05) from 1-7 h. This contrasted with the constant levels maintained during dialysis with UFH. FPA levels were significantly elevated after 2 h following the 1,250 AFXa u bolus and after 4 h following the 2,500 AFXa u bolus. There was no significant difference in FPA levels between the 5,000 AFXa u bolus and UFH. β-thromboglobulin (pTG) levels rose significantly towards the end of dialysis in all LMWH groups and, at 5 h, were significantly increased following the 5,000 AFXa u and 2,500 AFXa u doses when compared to the UFH regime. AFXa levels correlated negatively with FPA levels (r = -0.62; p <0.01). In conclusion, for administration of Innohep, a bolus dose of 2,500 AFXa u would appear to be sufficient for dialyses of short duration (up to 4 h), whilst a 5,000 AFXa u bolus is as effective as UFH for a 6 h dialysis. AFXa activity measured by CS assay is related to inhibition of fibrin formation and can be used for monitoring purposes.

• References

• 1 Bergqvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-91
• 2 Bratt G, Törnebohm E, Lockner D, Bergström K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemostas 1985; 53: 208-11
• 3 Holmer E, Lindahl U, Backstrom G, Thunberg L, Sandberg H, Soderstrom G, Andersson L. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-90
• 4 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralisation by platelet factor 4. Biochem J 1984; 218: 725-31
• 5 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-45
• 6 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 1984; 35: 613-25
• 7 Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemostas 1986; 56: 243-6
• 8 Mingardi G, Perico N, Pusineri F, Massazza M, Marchesi E, Mecca G, Remussi G, Donati MB. Heparin for hemodialysis: practical guidelines for administration and monitoring. Int J Art Organs 1984; 7: 269-74
• 9 Lane DA, Ireland H, Flynn A, Anastassiades E, Curtis JR. Haemodialysis with low MW heparin: Dosage requirements for the elimination of extracorporeal fibrin formation. Nephrol Dial Transplant 1986; 1: 179-87
• 10 Ireland H, Lane DA, Curtis JR. Objective assessment of heparin requirements for hemodialysis in humans. J Lab Clin Med 1984; 103: 643-52
• 11 Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemostas 1982; 48: 41-5
• 12 Ryan KE, Shepherd J, Flynn A, Ireland H, Lane DA, Curtis JR. Biocompatibility of cuprophane and polycrylonitrile membranes in haemodialysis; thrombotic potential and assessment of heparin dosage requirements. (In preparation.)
• 13 Schrader J, Valentin R, Tonnis H-J, Hildebrand U, Stibbe W, Armstrong VW, Kandt M, Kostering H, Quellhorst E. Low molecular weight heparin in hemodialysis and hemofiltration patients. Kidney Int 1985; 28: 823-9
• 14 Ireland H, Lane DA, Flynn A, Pegrum AC, Curtis JR. Low molecular weight heparin in haemodialysis for chronic renal failure: Dose finding study of CY222. Thromb Haemostas 1988; 59: 240-7
• 15 Anastassiades E, Lane DA, Ireland H, Flynn A, Curtis JR. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clin Nephrol 1989; 32 (12) 290-6
• 16 Tew CJ, Lane DA, Thompson E, Ireland H, Curtis JR. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222. Br J Haematol 1988; 70: 335-40
• 17 Hemker HC. The mode of action of heparin in plasma. In: XIth Congress Thrombosis and Haemostasis, Brussels.. Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds) Leuven Univ Press, Leuven: 1987. pp 17-36
• 18 Ofosu FA. Antithrombotic mechanisms of heparin and related compounds. In: Heparin. Chemical and Biological Properties, Clinical Applications.. Lane DA, Lindahl U. (eds) Edward Arnold, London: 1989
• 19 Cadroy Y, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): Comparison with standard heparin. J Lab Clin Med 1989; 114: 349-57
• 20 Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemostas 1989; 61: 7-9
• 21 Lane DA, Ryan K. Heparin and low molecular weight heparin: Is anti-factor Xa activity important?. J Lab Clin Med 1989; 114 (4) 331-3
• 22 Westwick J, Scully MF, Poll C, Kakkar W. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 1986; 42: 435-47